bringing novel prescription medicines
to the global market for essential supportive care for
people undergoing treatment for diseases such as cancer
Our mission is to develop and commercialize prescription medicines that support the comfort, quality of life, and dignity of people with treatment-related GI distress, specifically overactive bowel, which includes symptoms of chronic diarrhea, urgency, and incontinence.
Our paramount near-term clinical activity is our Phase 3 pivotal OnTarget trial of Mytesi® (crofelemer) for the follow-on indication of the preventative treatment of chemotherapy-induced overactive bowel (CIOB). We have completed patient enrollment for OnTarget – a key step on our journey to making crofelemer available to treat the neglected comorbidity of CIOB – and comprehensive results from this pivotal study are forthcoming.
We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected in 2024.
Our medicines are responsibly harvested from plants located in rainforest regions.
Our medicines work by a novel mechanism of action: the inhibitory modulation of two secretory chloride ion channels in the gastrointestinal tract.
bringing novel prescription medicines
to the global market for essential supportive care for
people undergoing treatment for diseases such as cancer
Our mission is to develop and commercialize prescription medicines that support the comfort, quality of life, and dignity of people with treatment-related GI distress, specifically overactive bowel, which includes symptoms of chronic diarrhea, urgency, and incontinence.
Our paramount near-term clinical activity is our Phase 3 pivotal OnTarget trial of Mytesi® (crofelemer) for the follow-on indication of the preventative treatment of chemotherapy-induced overactive bowel (CIOB). We have completed patient enrollment for OnTarget – a key step on our journey to making crofelemer available to treat the neglected comorbidity of CIOB – and comprehensive results from this pivotal study are forthcoming.
We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected in 2024.
Our medicines are responsibly harvested from plants located in rainforest regions.
Our medicines work by a novel mechanism of action: the inhibitory modulation of two secretory chloride ion channels in the gastrointestinal tract.
Napo Pharmaceuticals, Inc.
200 Pine Street, Suite 400
San Francisco, CA 94104
©2023 Napo Pharmaceuticals, Inc.
MYTESI® CALL CENTER
For product information, adverse event
reports, and product complaint reports,
please contact the Mytesi® Call Center at
(844) 722-8256 or by email at
product.inquiries@napopharma.com
Web Accessibility Feedback Email
Web Accessibility Feedback Form
MYTESI® CALL CENTER
For product information, adverse event
reports, and product complaint reports,
please contact the Mytesi® Call Center at
(844) 722-8256 or by email at
product.inquiries@napopharma.com
Web Accessibility Feedback Email
Web Accessibility Feedback Form
Napo Pharmaceuticals, Inc.
200 Pine Street, Suite 400
San Francisco, CA 94104
©2023 Napo Pharmaceuticals Inc.